- Investigator, Laboratory of Cancer Biology and Genetics
Dr. Li Yang is a Senior Investigator at the National Cancer Institute (NCI). She received her Ph.D. in the Department of Cancer Biology at Vanderbilt University, under the mentorship of Dr. David Carbone. Her dissertation research focused on COX-2 pathway in tumor progression, immune suppression, and the contribution of host myeloid cells to tumor blood vessel formation. She investigated TGF-β regulation of inflammation and tumor microenvironment during her postdoc research with Dr. Harold Moses. She joined NCI in 2009. Her research program is devoted to understanding the molecular mechanisms underlying tumor-stroma interaction during metastatic process.
Dr. Yang is a recipient of the Federal Technology Transfer Award, co-recipient of FLEX Program Awards for Principal Investigators, CCR, NCI, as well as U.S.-China Biomedical Collaborative Research Grant award.
Articles8
- (2020). Virtual care to increase military medical centre capacity in the primary health care setting: A prospective self-controlled pilot study of symptoms collection and telemedicine. JOURNAL OF TELEMEDICINE AND TELECARE.
- (2015). CCL9 Induced by TGF beta Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ. CANCER RESEARCH. 75(24), 5283-5298.
- (2015). CXCR3 as a molecular target in breast cancer metastasis: inhibition of tumor cell migration and promotion of host anti-tumor immunity. Oncotarget. 6(41), 43408-43419.
- (2015). Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS. 221(2), 509-517.
Academic Articles9
- (2020). Virtual care to increase military medical centre capacity in the primary health care setting: A prospective self-controlled pilot study of symptoms collection and telemedicine. JOURNAL OF TELEMEDICINE AND TELECARE.
- (2015). CCL9 Induced by TGF beta Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ. CANCER RESEARCH. 75(24), 5283-5298.
- (2015). CXCR3 as a molecular target in breast cancer metastasis: inhibition of tumor cell migration and promotion of host anti-tumor immunity. Oncotarget. 6(41), 43408-43419.
- (2015). Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS. 221(2), 509-517.